Moderna’s shot had efficacy of 94.5% in a preliminary analysis of a large late-stage clinical trial. It follows similar positive developments in a vaccination being jointly developed by Pfizer Inc. last week, buoying commodity prices globally.
More »
No comments:
Post a Comment